TOPICAL REVIEW

Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer

To cite this article: Joanna L Sylman et al 2017 Converg. Sci. Phys. Oncol. 3 023001

View the article online for updates and enhancements.

Related content
- Physics of Cancer: Inflammation and cancer
  C T Mierke
- Physics of Cancer: Initiation of a neoplasm or tumor
  C T Mierke
- Physics of Cancer: The impact of cells and substances within the extracellular matrix tissue on mechanical properties and cell invasion
  C T Mierke
Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer

Joanna L Sylman, Annachiara Mitrugno, Garth W Tormoen, Todd H Wagner, Parag Mallick and Owen J T McCarty

1 Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR, United States of America
2 VA Palo Alto Health Care System, Palo Alto, CA, United States of America
3 Department of Radiation Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, United States of America
4 Department of Radiology, Canary Center at Stanford, Stanford University School of Medicine, Stanford, CA, United States of America
5 Department of Surgery, Stanford University School of Medicine, Stanford, CA, United States of America
6 Author to whom any correspondence should be addressed: Department of Biomedical Engineering, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239, United States of America

E-mail: jsylman@stanford.edu

Keywords: platelets, cancer, thrombocytosis, thrombosis, metastasis

Abstract
Platelets are anucleate cells in the blood at concentrations of 150 000–400 000 cells µL⁻¹ and play a key role in hemostasis. Several studies have suggested that platelets contribute to cancer progression and cancer-associated thrombosis. In this review, we provide an overview of the biochemical and biophysical mechanisms by which platelets interact with cancer cells and review the evidence supporting a role for platelet-enhanced metastasis of cancer, and venous thromboembolism (VTE) in patients with cancer. We discuss the potential for and limitations of platelet counts to discriminate cancer disease burden and prognosis. Lastly, we consider more advanced diagnostic approaches to improve studies on the interaction between the hemostatic system and cancer cells.

Introduction
Platelets, present in the body at concentrations of 150 000–400 000 cells µL⁻¹, are anucleate cells that are derived from megakaryocytes in the bone marrow. The primary role of platelets is to seal sites of vascular damage or endothelial cell disruption as a means to prevent bleeding and promote wound healing.

Mechanistically, platelets are recruited to sites of vascular injury and adhere to newly exposed extracellular matrix proteins such as collagen, which bind platelet receptor GPIb–V–IX through von Willebrand factor (VWF) [1]. Once bound through GPIb–V–IX, the platelet receptor GPVI binds with collagen and activates via outside-in platelet signaling that results in calcium mobilization, cytoskeletal rearrangement, and release of α- and dense-granules, which contain the secondary platelet agonists adenosine phosphate (ADP) and thromboxane (TxA₂). Additionally, upon activation, procoagulant phosphatidylserine is exposed on the platelet surface, which serves as a site of catalysis for generation of the serine protease thrombin. Thrombin, aside from its role in fibrin formation, activates protease-activated receptors (PARs) and triggers G-protein–coupled receptors to drive intracellular signaling cascade resulting in the rapid shift of platelet integrins to their active conformation to promote stable platelet adhesion and aggregation [2–4].

Both clinical and experimental evidence has also implicated an important role for platelets in cancer. The relationship between hemostatic components and cancer was first established in the mid-nineteenth century by Trouseau, who detected a correlation between excessive blood clotting and an occult carcinoma [5]. Moreover, Theodore Billroth found histological evidence of tumor cells colocalized in thrombi, suggesting there might be an interaction between hemostatic and metastatic systems [6]. The interplay of cancer cells and platelets has been demonstrated throughout the progression of cancer, including tumor growth, angiogenesis, metastasis, and cancer-associated thrombosis.

In this review, we discuss the contributions of platelets to cancer metastasis and associated venous thromboembolism (VTE). First we describe the biophysical and biochemical interactions between cancer cells and platelets to potentiate thrombocytosis, metastasis, and VTE. Next, we discuss and summarize clinical studies that investigated the relationship between platelet...
count and cancer metastasis or VTE. We consider the limitations and potential opportunities of monitoring platelet count in cancer patients to discriminate disease stage and patient prognosis to influence targeted treatment plans. Lastly, we discuss the use of advanced diagnostics and longitudinal electronical medical record clinical data supported by the Veterans Health Administration (VHA) and the Big Data Scientist Training Enhancement Program (BD-STEP) to study the interaction of hemostatic and metastatic components.

**Contribution of platelets to cancer metastasis**

During the process of metastasis, cancer cells detach from a primary tumor site, intravasate the blood vessel lumen, travel through the circulatory system, and arrest at distant sites to form a metastatic niche [7]. Metastasizing tumor cells must endure the hydrodynamic shear forces inherent to the vasculature as well as evade immune system surveillance, which together, make the circulatory system a hostile environment. Experimental evidence indicates that platelets can exacerbate the process of cancer metastasis in a number of ways: shielding circulating tumor cells from recognition of natural killer cells, aiding tumor cell extravasation by encouraging and stabilizing tumor cell arrest in the vasculature and potentiating endothelial cell retraction, and stimulating tumor proliferation and angiogenesis by supplying the cancer cells with various growth factors [8–11]. Additionally, platelets can support the neovascularization of a tumor by providing a source of vascular endothelial growth factor (VEGF) contained in platelet α-granules [12]. In accordance with these findings, animal models have demonstrated a benefit of lowering platelet count in the inhibition of metastasis [13, 14].

**Biophysical mechanisms of platelet-mediated cancer metastasis**

Successful metastasis of tumor cells from a primary tumor may be affected by the biophysical-dependent interactions with platelets during their journey through the blood vessels. Circulating tumors cells (CTCs) must endure shear stress forces during the metastatic process, particularly during a phase in which they arrest on the luminal vessel wall prior to extravasation. Platelets are a potential mediator of tumor cell arrest, as they have the ability to tether, roll and arrest to a vessel wall at a wide range of shear stresses via interactions with shear-activated von Willebrand protein [13, 14]. Platelets express surface proteins such as αth/β3, a receptor involved in platelet aggregation, and P-selectin, a cell adhesion molecule. Both receptors have been shown to support and stabilize the adhesive interactions of colon carcinoma cells (LS174T and COLO205) with platelets cells in *vitro* up to wall shear stresses of 1.4 dyne cm⁻² [15].

In addition to influencing tumor cells arrest, physical properties of the microenvironment also affect tumor cell and platelet interactions that lead to heteroaggregate formation under flow. Heteroaggregate formation may be an important aspect of cancer cell survival, as platelets may provide a protective cloak for cancer cells from immune cells during hemogenous dissemination. The formation of heteroaggregates is a function of the fluid-mechanical environment, with *in vitro* studies showing that interactions between CTC and platelets are most favored in a low shear stress environment [16]. Successful metastasis may also be highly dependent on physical features of the cancer cells. Several studies have made efforts to identify the biophysical properties of cancer cells, such as their morphology, size, mass, volume and density variations that would be advantageous in predicting their tumorogenic potential [17–19]. In a computational model, it was demonstrated in a model coupling blood flow with advection-diffusion kinetics, that geometric measurements of CTCs and their respective aggregates drastically influenced the concentrations profiles of prothrombotic enzymes such as thrombin in flowing blood [20].

**Platelet-derived soluble factors and receptors promote metastasis**

Paracrine interactions between platelets and cancer cells facilitate the dissemination, survival and extravasation of cancer cells in the circulation. The α-granules of platelets are a source of transforming growth factor β (TGFβ), a secreted protein involved in the control of cell growth, cell proliferation, cell differentiation and apoptosis, and platelet derived growth factor (PDGF), a protein involved in cell growth and division and in promoting angiogenesis. These proteins both inhibit host immunosurveillance, and have thus been implicated in promoting tumor metastasis [21]. In addition to its role in protection cancer cells from a lethal immune response, TGFβ has been shown to enhance the invasive potential of cancer cells by activating the TGFβ/Smad and NF-KB signaling pathways in tumor cells necessary for the epithelial to mesenchymal transition [22]. Platelet dense granules secrete adenine nucleotides such as ADP and ATP, which have been shown to support the immune evasion and eventual extravasation of CTCs from the bloodstream, respectively. Specifically, platelet secretion of ATP, which can be induced by tumor cells, initiates a P2Y2 receptor-mediated signaling cascade in endothelial cells leading to the disaggregation of the endothelial barrier [23, 24] and creating a potential site for metastasizing tumor cells to arrest. Similarly, another molecule known as a metalloproteinase (MMP), released by both cancer cells or platelets, is known to degrade the extracellular matrix barrier and promote invasion and tumor extravasation [25] (figure 1).
Platelet membrane expression of proteins has been associated with improved adhesion of cancer cells to vessel walls and the increased ability of cancer cells to withstand shear stresses in the circulation. Similarly, activated platelets express phosphatidylserine, which catalyzes the production of thrombin and in turn converts fibrinogen into fibrin. Fibrin formation has been implicated in strengthening heterotypic platelet-cancer aggregates, ensuring their survival and transport to secondary sites [26].

**Activation of platelets by cancer cells**

During the process of hematogenous dissemination, cancer cells may activate platelets in the bloodstream [23, 27], a phenomenon known as tumor cell-induced platelet activation (TCIPA). Platelet activation in turn results in the release of the aforementioned platelet-derived growth factors and the formation of a fibrin-rich tumor cell platelet aggregates. This process has been proposed to act as a positive feedback activation loop during cancer metastasis. Moreover, tumor cell-induced platelet activation may play a role in the development of cancer-associated thrombosis [26, 28].

Tumor cells can induce platelet activation via a combination of juxtacrine and paracrine routes, occurring by physical engagement of platelet receptors by tumor cells or via synthesis and/or release of soluble agonists, respectively. The major platelet receptors mediating adhesive interactions with tumor cells are αIIbβ3 integrins and the adhesive molecule P-selectin. αIIbβ3 is a receptor for fibrinogen, fibronectin and VWF while P-selectin functions as receptor for mucin-type glycoproteins or sulfated glycolipids expressed on the surface of many types of cancer cells [10, 15, 29, 30]. Deficiency or blockade of αIIbβ3 or P-selectin has been shown to inhibit TCIPA in vitro and reduce of experimental metastasis in vivo in several mouse models of cancer [31–39].

The major soluble mediators found to induce TCIPA are thrombin, ADP, TxA2 and matrix metalloproteases (MMPs). Thrombin can be generated directly by procoagulant tumor cells, via tumor cell-derived microvesicles expressing tissue factor (TF), or indirectly by host tissues which have been damaged due to tumor cell invasion or chemotherapy [26, 40]. Platelet activation by thrombin results from the cleavage of protease activated receptors (PARs), which leads to the rapid release of ADP from platelet dense granules and synthesis and release of TxA2. Subsequently, ADP and TxA2 synergize to amplify the response of the platelets to cancer cells by binding to the P2Y12 and TxA2 platelet receptors, respectively. There is also evidence that platelets can be directly activated by ADP released from cancer cells. The proteolytic enzyme, MMP-2, released by tumor cells as a result of activation has been shown to contribute to TCIPA in vitro using HT-1080 fibrosarcoma and A549 lung epithelial carcinoma cell lines [32, 41, 42]. Alternatively, osteosarcoma and prostate cancer cells have been shown to trigger TCIPA in vitro via engagement of the platelet podoplanin receptor CLEC-2 and via activation of the platelet IgG receptor FcγRIIa [43, 44]. Experimental TCIPA and the metastatic progression of tumors, including neuroblastoma, lung, breast and pancreatic carcinoma and melanoma have been shown to be impaired in animal models by treatment with anticoagulants like heparin or low molecular weight heparin, or the P2Y12 inhibitors such as ticagrelor and clopidogrel, or by aspirin, which inhibits TxA2 synthesis [40, 45–51]. Collectively, these observations suggest that platelet receptors and ligands may be targeted to suppress cancer-induced platelet responses during metastasis (figure 2).

**Cancer cell-induced thrombocytosis**

Thrombocytosis, defined as a platelet count of >400 000 cells µl⁻¹ of blood, was first associated with cancer progression in 1872 by Riess and remains a marker of poor prognosis in patients with solid tumors [52]. The mechanism underlying cancer cell-induced thrombocytosis remains ill-defined. It has been suggested that cancer cell-induced thrombocytosis results from the overproduction of thrombopoietic
hormones acting on megakaryocytes and their precursors, such as thrombopoietin (TPO) which is synthetized and released in plasma by the liver. In vitro, three growth factors, including Interleukin (IL)-6, IL-1, and leukemia inhibitory factor, have been shown to be capable of promoting megakaryocytopenesis and subsequent thrombocytosis. Studies using mouse models of ovarian cancer have shown that tumor-derived IL-6 induces the synthesis and release of hepatic TPO. Moreover, high serum levels of IL-6 and TPO have been found to be associated with high platelet count in patients with ovarian cancer. Inhibition of IL-6 and TPO production with small interfering RNA brought the platelet count back within normal range in an animal model of ovarian cancer, as did the clinical use of the anti-IL-6 antibody siltuximab in patients with ovarian cancer [53].

Clinical studies: metastasis and platelets

The first observation of thrombocytosis accompanying metastasis was identified in 1964 in a clinical study by Levin and Conley in which they examined platelet counts of 14,000 patients admitted to Johns Hopkins hospital. Approximately 40% of the patients with malignant disease were found to have platelet counts greater than 400,000 cells µl⁻¹ in the absence of iron deficiency and benign inflammation. A number of subsequent studies also found a relationship between thrombocytosis and cancer. For instance, a 1970 study by Silvis et al. showed that 60% of a cohort of 190 patients with lung cancer had thrombocytosis [54], and in 1974, Tranum et al. reported that thrombocytosis occurred in patients with solid tumors [6]. Multivariate analyses confirmed that thrombocytosis was an independent contributing factor to metastasis while accounting for age and gender. Other studies demonstrating the association of thrombocytosis and metastasis are highlighted in table 1.

The reported occurrence of thrombocytosis in metastatic cancer patients varies widely in the literature, ranging from ~5–60%. Some of the disparities in reported results may be attributed to factors such as the type of cancer or the stage. For example, the percentage of patients with thrombocytosis was 3.7% for patients with breast cancer [55], whereas 24–63% [56] and 33–57% [53] in patients with renal or ovarian cancer, respectively. It has also been reported that patients with adenocarcinomas have an increased likelihood of metastasis and accompanying thrombocytosis; for instance, Zhang et al documented that 26.6% of 308 cases of histopathologically-confirmed lung adenocarcinomas presented with accompanying thrombocytosis [57]. Pedersen et al reported differences in the occurrence of thrombocytosis in cancer patients based on cancer histology, with squamous cell carcinoma at higher risk for thrombocytosis compared to non-squamous cell types [58, 59]. The occurrence of thrombocytosis in patients has been reported to vary depending on the stage of cancer, with later stage cancers being associated with increased platelet counts [58–60]. In a study of 398 lung cancer patients, the occurrence of platelet counts greater than 400,000 cells µl⁻¹ was reported to be 28.6% in Stage IV patients versus 18.6% in Stage I patients [59]. While the occurrence and extent of thrombocytosis in metastatic cancer patients seems to be dependent on the particular malignancy, a common finding of all the studies is that thrombocytosis in cancer patients is a hallmark of poor prognosis and a low survival rate.

Multivariate analyses and Cox survival models have confirmed that thrombocytosis in cancer patients is an independent predictor of poorer outcomes [58]. Symbas et al reported a shorter life expectancy in patients with renal cell cancer that presented with thrombocytosis [61]. In this study, the platelet counts were recorded for 259 patients with stage IV renal cell cancer who had undergone immunotherapy, chemotherapy, or hormonal therapy after surgery. Patients that had platelet counts greater than 400,000 cells µl⁻¹ were found to have lower survival compared to those with a platelet count below the aforementioned threshold. Zhang et al
Table 1. Clinical studies investigating the frequency of high platelet count in cancer patients and the role of high platelet count in patient outcomes.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Cancer type/stage</th>
<th>Number of patients</th>
<th>Time of platelet count measurement</th>
<th>Cut off platelet count (µl)</th>
<th>Occurrence&lt;sup&gt;a&lt;/sup&gt; (number of patients (%))</th>
<th>Outcome&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stone et al</td>
<td>Prospective</td>
<td>Epithelial ovaries/stages III and IV</td>
<td>619</td>
<td>Time of diagnosis</td>
<td>450 000</td>
<td>192 (31%)</td>
<td>OS: 2.62 versus 4.65 years (P &lt; 0.001)</td>
</tr>
<tr>
<td>Maraz et al</td>
<td>Retrospective</td>
<td>Lung/stages I–IV</td>
<td>398</td>
<td>Time of diagnosis</td>
<td>400 000</td>
<td>86 (22%) overall; 18.6% I, 19.3% II, 27.5% III, 28.6% IV</td>
<td>HR: 1.58 (P &lt; 0.001), OS: 38 versus 63.1 months (P = &lt;0.001)</td>
</tr>
<tr>
<td>Pederson et al</td>
<td>Retrospective</td>
<td>Lung/stages I–IV</td>
<td>1115</td>
<td>Time of diagnosis</td>
<td>400 000</td>
<td>357 (32%) overall; 23% I &amp; II, 37% III &amp; IV</td>
<td>RR: 4.24 (P &lt; 0.001)</td>
</tr>
<tr>
<td>Aoe et al</td>
<td>Retrospective</td>
<td>Lung/stages I–IV</td>
<td>611</td>
<td>Preoperative</td>
<td>400 000</td>
<td>98 (24%)</td>
<td>HR: 1.29 (P = 0.0348)</td>
</tr>
<tr>
<td>Taucher et al</td>
<td>Retrospective</td>
<td>Breast/I,II,IIIa</td>
<td>4300</td>
<td>Time of diagnosis</td>
<td>400 000</td>
<td>161 (3.7%) overall; 77 (3%) I, 77 (4.8%) II, 5 (3.8%) IIIa</td>
<td>RR: 1.73 (P = 0.0064), OS: 72 versus 99.5 months (P = 0.0054)</td>
</tr>
<tr>
<td>Herndon et al</td>
<td>Retrospective</td>
<td>Mesothelioma</td>
<td>336</td>
<td>No chemo, &gt;2 weeks after surgery</td>
<td>400 000</td>
<td>184 (54.8%)</td>
<td>RR: 1.57 (P &lt; 0.001)</td>
</tr>
<tr>
<td>Ishikawa et al</td>
<td>Retrospective</td>
<td>Colorectal/stages I–IV</td>
<td>453</td>
<td>Preoperative</td>
<td>300 000</td>
<td>226 (49.9%) overall; 159 (45.7%) I, II, III, 67 (63.8%) IV</td>
<td>OR: 1.64 (P = 0.039) (after surgery)</td>
</tr>
<tr>
<td>Bensalah et al</td>
<td>Retrospective</td>
<td>Renal/stages I–IV</td>
<td>804</td>
<td>Preoperative</td>
<td>450 000</td>
<td>63 (7.8%) overall; 16 (4%) T1 or 2, 47 (11.6%) T3 or T4</td>
<td>RR: 1.8 (P &lt; 0.001)</td>
</tr>
</tbody>
</table>

HR, hazard ratio; OR, odd ratio; OS, overall survival; RR, relative risk.
<sup>a</sup> Refers to the number and percentage of patients that had thrombocytosis.
<sup>b</sup> Outcomes refers to patients that had thrombocytosis.
<sup>c</sup> OS is showing survival of patients with thrombocytosis versus patients without thrombocytosis.
also demonstrated via log rank tests that there was a significant difference in survival between patients with and without thrombocytosis, as the former had an increased risk of bone metastases [57].

For the majority of the clinical studies, platelet counts were recorded at the time of diagnosis, before or after operations, or during chemotherapy treatment. Yet it is unknown at what point elevated platelet counts occur in the progression of disease; there is a possibility that it could precede cancer progression by months or even years. Several of the clinical studies, both retrospective and prospective, provided platelet counts at the times of diagnosis, prior to implementing an intervention. Once an intervention is initiated, it is likely that platelet counts become highly variable, and thus may not provide as much predictive power or would be a biased predictor due to unobserved heterogeneity. Platelet counts obtained following radiotherapy, chemotherapy, or surgical resection would likely be highly dependent on the intervention itself. For instance, in a study of stage IV renal cell cancer patients by Symbas et al, platelet count was reported to be affected by immunotherapy, chemotherapy, and hormonal therapy [61]. Moreover, in a study of 269 lung cancer patients undergoing surgery, Pederson et al reported that after one to three months after the surgical resection, only 8.9% of the patients had platelet counts greater than 400,000 cells µl\(^{-1}\) as compared to incidences of 20–30% found before the operation. Yet only thrombocytosis prior to the treatment had an influence on the survival rate in surgically resected patients. Given the susceptibility of platelet counts to vary as a result of surgery, it is uncertain if the changes in the incidence of thrombocytosis could be attributed to differential surgery-related inflammation, or from the removal of the tumor.

One study on the association between thrombocytosis and outcomes in ovarian cancer patients suggested a role for cancer in the promotion of platelet production. A possible mechanism is the promotion of megakaryocytopenia by tumor-derived humoral agents, resulting in the enhancement of circulating platelets count. For instance, IL-6, a known potent stimulator of megakaryocytopenia, has been shown to be released from tumor cells in vitro and in vivo. Out of a 619 cohort of epithelial ovarian cancer patients, 192 patients were reported to have platelet counts above normal (>450,000 cells µl\(^{-1}\)). Moreover, the IL-6 and thrombopoietin plasma levels were found to be significantly higher in a cohort of 46 patients with epithelial ovarian cancer and thrombocytosis as compared to a cohort of 104 patients with epithelial ovarian cancer and normal platelet counts. A potential mechanism to explain the author’s findings is that tumor-derived IL-6 stimulated the liver to produce increased TPO levels resulting in increased platelet production. The authors demonstrated that blocking IL-6 and TPO production with a small interfering RNA led to normalization of platelet counts in an animal model of ovarian cancer. Additionally, IL-6 was targeted with siltuximab (an anti-IL-6 antibody) and combined with paclitaxel (common chemotherapeutic agent for epithelial ovarian cancer), which significantly reduced tumor growth in the mouse models. From such work, it is conceivable that drugs reducing platelet counts or platelet activation might attenuate cancer progression and improve survival rate of patients. In the following section, we describe treatments that act on platelets and may interfere with cancer progression.

### Treatment and prevention of cancer metastasis

Several therapeutic strategies targeted toward platelet production or activation have been evaluated for their efficacy and safety in inhibiting cancer metastasis. One such strategy that has shown promise is the long-term use of low dose aspirin. Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX), the enzymes responsible for the synthesis of prostaglandins. An isoform of COX, known as COX-2 has been found to be overexpressed in cancer cell lines and has been implicated to play a role in carcinogenesis, tumor growth, apoptosis, and angiogenesis. Aspirin has been reported to reduce risk of colorectal cancer and some other cancers in clinical studies. In a 2012 meta-analysis of 5 randomized clinical trials assessing aspirin use in 17,285 participants, aspirin treatment reduced the risk of distant metastasis (0.64 HR, 95% CI 0.48–0.84, \(p = 0.001\)), especially in adenocarcinomas (0.54 HR, 95% CI 0.38–0.77, \(p = 0.0007\)) regardless of whether or not they had metastasis [62]. Benefits of regular aspirin use has been found to depend on the type of cancer and the duration of the treatment. For example, in a meta-analysis of 51 randomized clinical trials comprising a total of 77,549 participants, daily aspirin intake reduced cancer mortality (0.85 HR, 95% CI 0.76–0.96), notably demonstrating the greatest clinical benefit when assessed after 5 years [62]. Epidemiological studies of colorectal patients from 30 studies and 37,500 cases reported a 30% reduction in the risk of cancer after use of regular/high dose aspirin for at least 5 years. Aspirin was also found to have a favorable effect on cancers of the esophagus, stomach, breast, ovary, and lung, but was deemed ineffective for pancreatic, prostate, and bladder cancer, and could be harmful in kidney cancer. However, in randomized studies including the Physicians Health Study [63] and Women’s Health Study [64], no association was found between use of aspirin and incidence of total, breast or colorectal cancer. Similarly, in the Women’s Health Study, low-dose aspirin (100 mg) was not found to reduce the risk of breast or colorectal cancer in 39,942 women over the course of 10 years [64].

Beyond inhibiting platelet activation with aspirin, several studies have evaluated the effect of lowering overall platelet count on outcome in cancer patients.
In a small-scale study of ovarian cancer patients, it was reported that clinical use of an anti-IL-6 antibody, siltuximab, reduced platelet count after 3 weeks of treatment, and inhibited tumor growth in 8 of 18 ovarian cancer patients receiving siltuximab [53]. Taken together, these studies suggest that pharmacological targeting of platelet activation or production may provide benefit in the treatment of cancer.

**Role of platelets and cancer in VTE**

The risk of a VTE is approximately seven times higher in patients with active cancer [65], yet it is unclear whether platelet–tumor cell interactions play a causative role in cancer-associated thrombosis. Several studies from the 1990s reported that the incidence of thromboembolic episodes and thrombocytosis in cancer patients was not correlated [58, 66], while a number of clinical studies conducted in the early 2000s reported an association of cancer-associated thrombocytosis with VTE. Complicating epidemiological studies is the inherent difficulty in determining actual VTE rates, as only a fraction of VTE are clinically evident and therefore discovered. Moreover, Zakai et al estimated that only actually 6% of DVTs are reported as symptomatic, and therefore the majority of incidences go unnoticed, resulting in an inaccurate prediction of VTE risk associated with cancer [67]. Clinical studies on thrombocytosis and VTE are summarized in Table 2. One such retrospective case control study compared the risk factors of VTE for medical inpatients with comparable rates of known malignancy in VTE cases (n = 65, 25% with known malignancy) versus non VTE cases (n = 123, 22% had no known malignancy). In this study, patients with platelet counts exceeding 350 000 cells μl⁻¹ had a 2.5-fold risk of developing VTE during hospitalization [67]. Similarly, in the outpatient setting, the ANC Study Group Registry prospectively analyzed 3003 patients with specific tumor types (breast, lung, ovarian, sarcoma, colon, lymphoma) at the start of their new chemotherapy regimen. They found an incidence of VTE of 3.98% in patients with prechemotherapy platelet counts greater than or equal to 350 000 cells μl⁻¹ compared to a 1.25% VTE incidence in patients with a platelet counts less than or equal to 200 000 cells μl⁻¹ [68]. Another study investigating 665 patients with solid tumors of the breast, lung, gastrointestinal tract, pancreas, kidney, or prostate, demonstrated that with higher platelet count threshold of 443 000 cells μl⁻¹, probabilities of risk were more accurately discriminated: the risk for VTE below the threshold was 5.9% versus 34.3% for patients with platelet counts greater than the threshold [69].

The risk for VTE in patients with cancer has been found to have a temporal relationship with time of diagnosis, with incidence of VTE being the highest in the first few months after cancer diagnosis. However, it remains unknown if this phenomenon is representative of a naturally occurring biological mechanism, or whether VTE occurrences can be owed to interventions such as surgery or chemotherapy. Interestingly, it has been shown that VTE are the leading significant cause of death in patients undergoing chemotherapy. For instance, Zakai et al reported that up to 21.5% of VTEs occur following non-surgical hospital admission in patients receiving chemotherapy. Though the actual process of chemotherapy can cause thrombocytopenia (low platelet count), as the treatment suppresses platelet count in the bone marrow [70], it has been determined that elevated pre-chemotherapy platelet counts are associated with worse VTE outcomes [68]. In addition to a high platelet count prior to the treatment, certain chemotherapy regimens have been shown to impose its own increased risks of VTE. In one such study, Blom et al investigated 3,220 patients of various types of cancer and reported that chemotherapy and hormonal therapy lead to a 2.2-fold and 1.6-fold increased risk of VTE, respectively [71]. Chemotherapy combined with the use of immunomodulatory agents such as thalidomide or lenalidomide or anti-angiogenic vehicles are known to increase the risk of VTE, prompting the recommendation of thromboprophylaxis when this drug cocktail is administered [72]. Erythropoiesis-stimulating agents (ESA) such as erythropoietin and darbepoetin are given to patients to enhance hemoglobin and red blood cell production during chemotherapy treatments. Notably, ESA therapy has been associated with a 50% increase in the risk of VTE in cancer patients and can cause iron restricted erythropoiesis and thrombocytosis, all of which is enhanced when accompanied by chemotherapy and radiation [68, 73]. In a study of 187 cancer patients, iron substitution was found to reduce the incidence of thrombocytosis and VTE compared to control patients [74]. Surgery has also been suggested as a potential risk for VTE progression in cancer patients. Several studies have reported that patients with cancer who underwent surgical intervention had either negligible or up to a 4-fold increase risk for postoperative VTE [71]. In summary, these studies suggest that having a high platelet count coupled with interventional treatments might increase the risks for deleterious cardiovascular events and worsen patient outcomes.

When platelets become activated, they discharge prothrombotic molecules from their α- and dense-granules into the blood microenvironment, which may represent a mechanism of action linking increased platelet count with cancer-associated VTE. One of the molecules contained in α-granules, P-selectin, is a member of the selectin family of cell adhesion molecules. P-selectin can also be released from the Weibel–Palade bodies of endothelial cells [75], and is known to play a role in thrombus formation. As mentioned previously, P-selectin has been shown to mediate platelet and leukocyte adhesion to cancer cell lines in vitro [29]. Soluble levels of plasma P-selectin is a known biomarker of platelet activation. In clinical studies, levels of soluble P-selectin have been shown to correlate with acute VTE and risk of VTE in patients [76]. In another
A prospective study of 687 cancer patients, it was shown that the risk of VTE was 12% in patients with soluble P-selectin levels above the 75th percentile compared to 4% of patients with soluble P-selectin levels under the threshold (2.6 HR, 95% CI 1.4–4.9, \( P = 0.003 \)) [77].

Platelet activation leads to the flipping of the platelet membrane to expose a procoagulant phosphatidylserine (PS)-rich surface. The PS surface acts as a site of catalysis for thrombin generation, with thrombin generation and the presence of PS-positive microparticles serving as biomarker for thrombosis. In the CATS study, it was found that elevated thrombin generation in patient plasma is associated with an increased risk of VTE [78], reporting that 11% of patients with elevated thrombin generation presented with a VTE and a worse prognosis (2.1 HR). While no association has been reported between procoagulant microparticles and occurrence of VTE, increased levels of PS-positive microparticles have been reported in cancer patients as compared to healthy controls [79].

VTE occurs in ~1–20% of inpatients, and is dependent on the severity of the malignancies; the presence of cancer increases the risk of a VTE by 4–7 fold [65]. The association between cancer and thrombosis is bidirectional, such that a VTE occurrence is indicative of cancer progression and a worse prognosis than the patients that do not experience VTE. More specifically, a VTE is correlated with poor survival and a decreased response to surgery and chemotherapy in lung, breast, colorectal, renal, and gastric cancers [80]. Moreover, it has been found that a VTE in patients initially diagnosed with local regional stage cancer have lower survival rates. As such there has been a need for risk assessment to improve clinical decision making and determine which patients will benefit most from prophylaxis. The Khorana risk assessment for cancer patients at the time of chemotherapy initiation was developed to identify patients with high risk of developing VTE [81]. The Khorana score assigns point values for a range of parameters based on logistic regression coefficients attained in the model. The score assigns 2 points for high risk cancer sites for gastric or pancreatic, 1 point for lung, ovarian, bladder, and 1 point for platelet counts exceeding 350 000 cells \( \mu l \), hemoglobin less than or equal to 10 g dl\(^{-1} \), leukocyte counts greater than 110,000 cells \( \mu l \) and a body mass index greater than or equal to 35 kg \( m^2 \). Patients are stratified into three categories for risk: low, intermediate, and high. Khorana et al determine that patients that had scores of 0, 1–2, and 3, had VTE risks of 0.3%, 2% and 6.7%, respectively, during the 2.5 follow-up period [81]. The Khorana score has been validated in the Prophylaxis of Thromboembolism during Chemotherapy study [82] and was used to assess more than 12,000 patients in cohort studies including Vienna CATs. The score has been improved for chemotherapy patients by also accounting for chemotherapy associated risks such as platinum and gemcitabine-based chemotherapy [82], where treatment with cisplatin or carboplatin-based chemotherapy or gemcitabine adds 1 point or 2 points, respectively. Later studies have even begun to include additional biomarkers such as soluble P-selectin and D-dimer levels in an expanded risk assessment model known as the Vienna prediction score [77, 83], as it was shown that patients with a score of 4 had a cumulative probability of 20.4% of a VTE occurrence, while those with a score greater than 5 had 35% probability of a VTE, but quantitative P-selectin biomarker assays have been difficult to implement across several studies due to poor standardization [77, 84].

Several studies have determined that the type of cancer and the rate of growth are important predictors of VTE risk [85–87]. Buller et al reported that mucinous adenocarcinomas are associated with a higher incidence of VTE [65, 88]. Additionally, it was demonstrated that patients with hematological malignancies such a lymphoma, leukemia, and myeloma had more incidences of VTE [86, 87]. Moreover, the SEER and Medicare data [89] demonstrated that recurrent thrombosis increased the risk of thrombosis in the subsequent two years and that patients with lung, stomach, or pancreas cancer were more likely to develop distant metastases within a year following a VTE episode. All in all, the development of a VTE in a cancer patient is a complex process.

Table 2. Clinical studies investigating the effect of platelet count on the occurrence of VTE and patient outcomes.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Cancer type</th>
<th>Patients</th>
<th>Treatments</th>
<th>Follow up (median)</th>
<th>Probability of VTE ( a )</th>
<th>Outcome ( a )</th>
</tr>
</thead>
<tbody>
<tr>
<td>CATS, Simanek et al</td>
<td>Prospective</td>
<td>Multiple solid tumors</td>
<td>665</td>
<td>Chemotherapy</td>
<td>12 months</td>
<td>34.3% versus 5.9%</td>
<td>HR: 3.5 (( P = 0.0032 ))</td>
</tr>
<tr>
<td>Khorana et al</td>
<td>Prospective</td>
<td>Breast, lung, ovarian, sarcoma, colon, and lymphomas</td>
<td>3003</td>
<td>Chemotherapy</td>
<td>2.4 months</td>
<td>3.98% versus 1.25%</td>
<td>OR: 2.81 (( P &lt; 0.002 ))</td>
</tr>
<tr>
<td>Mandala et al</td>
<td>Prospective</td>
<td>Breast and gastrointestinal</td>
<td>381</td>
<td>Adjuvant chemotherapy</td>
<td>35 months</td>
<td>Not reported</td>
<td>HR: 1.65 (( P &lt; 0.0341 ))</td>
</tr>
<tr>
<td>Henry et al</td>
<td>Retrospective</td>
<td>Multiple</td>
<td>187</td>
<td>ESA therapy</td>
<td>Not applicable</td>
<td>Not reported</td>
<td>OR: 2.9 (( P = 0.036 ))</td>
</tr>
</tbody>
</table>

HR, hazard ratio; OR, odd ratio; ESA, erythropoietic stimulating agents.

\( a \) Refers to the probability of a VTE in a cancer patients with and without thrombocytosis.

\( b \) Outcomes refers to patients that had thrombocytosis.
that is related to the many factors involved in the specific characteristics of each cancer, the accompanying blood components, and treatment approaches.

Potential value and limitations of platelet counts

Platelet counts are routinely obtained in patients with cancer undergoing treatment, yet it is not yet clear how or if to incorporate these data into management of patients with cancer. Platelet counts might prompt decisions regarding the administration of anti-platelet therapies or anticoagulant prophylaxis. However, given the susceptibility of platelet count to change in response to a variety of endogenous and exogenous factors, there is a need to analyze temporal platelet count variations as a function of the cancer stage and the type of therapeutic treatment. Additionally, a limitation of only considering platelet counts as a measured biomarker is that they do not provide functional data on platelet activation, granule content or other mechanisms by which platelets and cancer cells may interact. Platelet function analyzers may provide information on platelet function with regards to hemostasis, but have not been validated with respect to cancer–platelet cell interactions or how to utilize this assay for managing patients with cancer. As more understanding of the interplay between platelets and cancer progression ensues, new opportunities to leverage existing assays to provide more insight, or development of novel assays to delineate cancer cell–platelet interactions within patients are needed. One such promising method is utilizing biological systems and multi-omics approaches, which will be discussed in the following section.

Big data and biological systems approaches

One approach to overcome the limitations of using platelet counts as biomarkers would be to leverage longitudinal electronic health information, ideally with information prior to cancer. The Department of Veterans Affairs (VA) treats more than 6 million patients annually and it routinely creates national databases from its electronic medical record, which was initiated in the early 1990s. Researchers can access information on laboratory tests, radiographic scans and procedures, thus offering researchers the ability to data mine and analyze a vast amount of longitudinal data from 100 000 s to millions of patients. Lab counts are routinely obtained from veterans and sampled from healthy and unhealthy patients. This rich database enables researchers to determine temporal features of lab counts that have the potential to influence a patient’s survival, recurrence, or response to treatment. In addition, the VA has teamed up with the National Cancer Institute (NCI) to fund the Big Data Scientist Training Program (BD-STEP), an initiative that is designed to help train researchers interested in such these opportunities and aims to improve veteran health through evidence based research.

Although the VA captures information on platelets from blood tests, it is increasingly capturing genomic and proteomic information from patients. This is useful, because as noted above, the mechanisms by which platelets impact cancer phenotypes span diverse regulatory scales from genomic alterations and evolution through metabolic flux. Consequently, beyond collecting platelet counts as biomarkers, multi-scale and multi-omics approaches should also be considered to uncover the complex mechanisms underlying the interactions between platelets and cancer. In particular, the collective genomes, transcriptomes and proteomes of cancer cells have the potential to offer insight into complex platelet and cancer cell interactions that enable thrombocytosis, cancer metastasis and thrombosis. By integrating diverse multi-scale and multi-omic data (tissue-scale imaging, pathology, molecular characterization) of platelet cancer interactions it may ultimately be possible to use these diverse data to assist in predicting patient outcomes and inform clinical decision making. Bioinformatics approaches would be particularly useful in determining the mechanistic underpinnings of thrombocytosis. Though thrombocytosis is a common clinical scenario, the diagnostic process can be challenging, because it is associated with a multitude of reactive processes such as infection, cancer, tissue damage, or chronic inflammatory disorders, or a clonal disorder [90]. Tumor cell multi-omes could aid in discriminating their relative contribution to elevated platelet counts. Incorporation of genomic data has already been instrumental in detection of the cause of clonal thrombocytosis, as it is associated with a BCR-ABL1 fusion in chronic myeloid leukemia [90, 91]. An additional known point mutation in exon 14 of the Janus kinase 2 (JAK2) gene can result in the JAK2V617F protein which is associated with polycythemia vera, essential thrombocythemia, and primary myelofibrosis [92–96]. Multi-omics approaches could also be used to determine whether the etiologies of metastatic potential and thrombogenicity of the circulating tumor cells are from mutations in the genome or epigenetic or protein modifications incurred by the tumor cell microenvironment. All in all, multi-omic data would be useful in determining the mechanisms of thrombocytosis, metastasis and thrombocytosis, and also provide support for the use of targeted therapies.

Other hematological related molecules may also help contribute to predicting patient metastasis and VTEs in patients. In 2007, the American Society of Clinical Oncology made recommendations for tumor markers for patient prognosis in breast cancer, which included urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1). uPA and PAI-1 are known proteins involved in regulating clot digestion, but also play essential roles in tumor invasion and metastasis. Low levels of uPA and PAI-1 in tissue measured by enzyme-linked immunosorbent
assays (ELISA) are associated with a low risk of recurrence [97] while their overexpression is associated with poor prognosis in early-stage breast cancer [98–100]. Other studies have confirmed that PAI-1 and uPA are strong prognostic factors independent of size, grade, and hormone receptor status in patients that did not receive adjuvant systemic therapy [100–102]. Additional molecules that might also be leveraged to predict cancer patients risk of VTEs include soluble P-selectin and microvesicles released from activated or apoptotic cell membranes once standardized measurement methods are available [103].

Conclusions

In the review, we summarized the biophysical and bidirectional biochemical interactions between cancer cells and platelets that are associated with the progression of cancer metastasis and thrombosis. We subsequently summarized studies that measured the correlation between thrombocytosis and cancer metastasis and thrombosis. We discussed some potential and limitations of leveraging platelet counts to predict the outcomes of cancer patients and describe the utility of multi-omics and longitudinal data mining approaches to be able to determine respective contributions of proteogenomic and temporal features in promoting lethal cancer and platelet interactions.

Acknowledgments

JLS is supported by the Big Data Scientist Training Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association Enhancement Program (BD-STEP) fellowship. This work was also supported by grants from the National Institutes of Health (R01HL101972) and the Altarum Institute. OJTM is an American Heart Association Institute. OJTM is an American Heart Association

Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

References

[22] Labelle M, Begum S and Hynes R O 2011 Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis Cancer Cell 20 576–90
[29] Chen M and Geng J G 2006 P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis Arch. Immunol. Ther. Exp. 54 75–84
platelet aggregation by antibodies to platelet glycoproteins Ib and Honn K V 1987 Inhibition of human tumor cell induced
metalloproteinase stimulates tumour cell-induced platelet
and Radomski M W 2004 Platelets, protease-activated receptors,
deficiency attenuates tumor growth and metastasis
by platelets during tumor cell-induced platelet activation
Pacchiarini L, Zucchella M, Milanesi G, Tacconi F, Bonomi E,
Cooperatives with venous thrombosis risk score
Pabinger I 2010 High platelet count associated with venous
thrombosis in a large cohort of 66 329 cancer patients: results
Carrier M, Le Gal G, Tay J, Wu C and Lee A Y 2011 Rates of
thrombocytosis in renal cell carcinoma J. Urol. 175 859–63
Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients Oncol. Lett. 9 762–8
Pedersen L M and Milman N 1996 Prognostic significance
Kaushansky K 2008 Historical review: megakaryopoiesis and thrombopoiesis Blood 111 981–6
Carrier M, Le Gal G, Tay J, Wu C and Lee A Y 2011 Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or
lenalidomide: a systematic review and meta-analysis
[73] Bennett C L et al 2008 Venous thromboembolism and
mortality associated with recombinant erythropoietin and
darbepoetin administration for the treatment of cancer-
associated anemia JAMA 299:914–24
Thrombocytosis and venous thromboembolism in cancer
patients with chemotherapy induced anemia may be related
to ESA induced iron restricted erythropoiesis and reversed
by administration of IV iron Am. J. Hematol. 87:308–10
Sixma J J and Nieuwenhuis H K 1997 The origin of P-selectin
as a circulating plasma protein Thromb. Haemost. 77:1081–5
[76] Blann A D, Noteboom W M and Rosendaal F R 2000 Increased
soluble P-selectin levels following deep venous thrombosis:
[77] Ay C et al 2008 High plasma levels of soluble P-selectin
are predictive of venous thromboembolism in cancer patients:
results from the Vienna Cancer and Thrombosis Study (CATS)
Blood 112:2703–8
[78] Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C,
Zielinski C and Pabinger I 2011 Prediction of venous
thromboembolism in patients with cancer by measuring
thrombin generation: results from the Vienna Cancer and
Thrombosis Study J. Clin. Oncol. 29:2099–103
Circulating procoagulant microparticles in cancer patients
[80] Sørensen H T, Mellemkjaer L, Olsen J H and Baron J A
2000 Prognosis of cancers associated with venous
[81] Khorana A A, Kuderer N M, Culakova E, Lyman G H and
Francis C W 2008 Development and validation of a predictive
model for chemotherapy-associated thrombosis Blood
111:4902–7
2012 A modified Khorana risk assessment score for venous
thromboembolism in cancer patients receiving chemotherapy:
the ProPhet score Intern. Emerg. Med. 7:291–2
Simanek R, Quehenberger P, Zielinski C and Pabinger I 2010
Prediction of venous thromboembolism in cancer patients
Blood 116:5377–82.
[84] Pabinger I and Ay C 2012 Risk of venous thromboembolism
and primary prophylaxis in cancer. Should all patients receive
thromboprophylaxis? Hämostaseologie 32:132–7
[85] Alcalay A, Wun T, Khatri V, Chew H K, Harvey D, Zhou H and
White R H 2006 Venous thromboembolism in cancer patients
with colorectal cancer: incidence and effect on survival J. Clin.
Oncol. 24:1112–8
Incidence of venous thromboembolism and the impact on
survival in breast cancer patients J. Clin. Oncol. 25:70–6
Malignancies, prothrombotic mutations, and the risk of
venous thrombosis JAMA 293:715–22
[88] Mandala M et al 2010 Acquired and inherited risk factors
for developing venous thromboembolism in cancer patients
receiving adjuvant chemotherapy: a prospective trial Ann.
Oncol. 21:671–6
[89] Marks M A and Engels E A 2014 Venous thromboembolism
and cancer risk among elderly adults in the US Cancer
Epidemiol. Biomarkers Prev. 23:774–83
evaluation, thrombotic risk stratification, and risk-based
management strategies Thrombosis 2011 e536062
Educ. Prog. 2009:159–67
[92] Baxter E J et al 2005 Acquired mutation of the tyrosine kinase
JAK2 in human myeloproliferative disorders Lancet Lond.
Engl. 365:1054–61
[93] James C et al 2005 A unique clonal JAK2 mutation leading
to constitutive signalling causes polycythaemia vera Nature
434:1144–8
[94] Kralovic R, Passamonti F, Buser A S, Teo S-S, Tiedt R,
Passweg J R, Tichelli A, Cazzola M and Skoda R C 2005 A gain-
of-function mutation of JAK2 in myeloproliferative disorders
[95] Levine R L et al 2005 Activating mutation in the
tyrosine kinase JAK2 in polycythaemia vera, essential
thrombocythaemia, and myeloid metaplasia with
myelofibrosis Cancer Cell 7:387–97
[96] Goerttler P S, Steinle C, März E, Johansson P L, Andreasson B,
Griesshammer M, Gisslinger H, Heimpel H and Pahl H L
2005 The JAK2V617F mutation, PRV-1 overexpression, and
EEC formation define a similar cohort of MPD patients Blood
106:2862–6
[97] Harris L, Fritsche H, Mennel R, Norton L, Radvan P, Taube S,
Sommerfield M R, Hayes D F and Bast R C 2007 American
society of clinical oncology 2007 update of recommendations
25:5287–312
[98] Duffy M J 2002 Urokinase plasminogen activator and its
inhibitor, PAI-1, as prognostic markers in breast cancer: from
pilot to level 1 evidence studies Clin. Chem. 48:1194–7
Kramer M D, Jänicek F and Klijn J G 1994 Plasminogen
activator inhibitor-1 and prognosis in primary breast cancer
[100] Look M P et al 2002 Pooled analysis of prognostic impact
of urokinase-type plasminogen activator and its inhibitor
PAI-1 in 8377 breast cancer patients J. Natl Cancer Inst.
94:116–28
[101] Harbeck N, Schmitt M, Kates R E, Kiechle M, Zemzoum L,
Jänicek F and Thomssen C 2002 Clinical utility of urokinase-
type plasminogen activator and plasminogen activator
inhibitor-1 determination in primary breast cancer tissue
for individualized therapy concepts Clin. Breast Cancer
3:196–200
[102] Zemzoum L et al 2003 Invasion factors uPA/PAI-1 and HER2
status provide independent and complementary information
Oncol. 21:1022–4
identified by a national cancer institute/national heart, lung,
and blood institute strategic working group Cancer Res.
76:3671–5